Literature DB >> 17975980

Expression of vascular endothelial growth factor in tumors and plasma from dogs with primary intracranial neoplasms.

John H Rossmeisl1, Robert B Duncan, William R Huckle, Gregory C Troy.   

Abstract

OBJECTIVE: To quantitatively evaluate expression of vascular endothelial growth factor (VEGF) in intracranial tumors in dogs and determine whether relationships exist between circulating and intratumoral VEGF concentrations and tumor type and grade. ANIMALS: 27 dogs with primary intracranial neoplasms and 4 unaffected control dogs. PROCEDURES: Plasma and brain tumor samples were obtained from each dog, and plasma and intratumoral concentrations of VEGF were measured by use of an ELISA.
RESULTS: Dogs with meningiomas (n = 11) were significantly older than dogs with oligodendrogliomas (7) or astrocytomas (9). Measurable VEGF was detected in all tumors, and a significant negative correlation between age and intratumoral VEGF concentration was detected. Age-adjusted comparisons identified significant differences in intratumoral VEGF concentrations among all tumor types; the highest VEGF concentrations were associated with astrocytomas. Within each tumor type, increasing tumor grade was significantly associated with increasing VEGF expression. Plasma VEGF concentrations were detectable in 9 of 27 dogs; the proportion of dogs with astrocytomas and a detectable circulating VEGF concentration (7/9 dogs) was significantly higher than the proportion of dogs with meningiomas (1/11 dogs) or oligodendrogliomas (1/7 dogs) with a detectable circulating VEGF concentration. CONCLUSIONS AND CLINICAL RELEVANCE: Overexpression of VEGF appears common in canine astrocytomas, oligodendrogliomas, and meningiomas. In the neoplasms examined, intratumoral VEGF concentrations correlated well with tumor malignancy. The VEGF expression patterns paralleled those of analogous human tumors, providing evidence that dogs are a suitable species in which to study angiogenesis and intracranial neoplasia for human application.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975980     DOI: 10.2460/ajvr.68.11.1239

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  12 in total

Review 1.  Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

Authors:  Michael R Olin; G Elizabeth Pluhar; Brian M Andersen; Rob Shaver; Nate N Waldron; Christopher L Moertel
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

2.  Expression and targeting of transcription factor ATF5 in dog gliomas.

Authors:  D York; C D Sproul; N Chikere; P J Dickinson; J M Angelastro
Journal:  Vet Comp Oncol       Date:  2017-05-08       Impact factor: 2.613

3.  Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas.

Authors:  A Courtenay Freeman; Simon R Platt; Shannon Holmes; M Kent; Kelsey Robinson; Elizabeth Howerth; Joe Eagleson; Alexandros Bouras; Milota Kaluzova; Constantinos G Hadjipanayis
Journal:  J Neurooncol       Date:  2018-01-19       Impact factor: 4.130

Review 4.  Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.

Authors:  John H Rossmeisl; Paulo A Garcia; Gregory B Daniel; John Daniel Bourland; Waldemar Debinski; Nikolaos Dervisis; Shawna Klahn
Journal:  Vet Radiol Ultrasound       Date:  2013-11-13       Impact factor: 1.363

Review 5.  Dogs are man's best friend: in sickness and in health.

Authors:  R Timothy Bentley; Atique U Ahmed; Amy B Yanke; Aaron A Cohen-Gadol; Mahua Dey
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

6.  Chromosomal Aberrations in Canine Gliomas Define Candidate Genes and Common Pathways in Dogs and Humans.

Authors:  Peter J Dickinson; Dan York; Robert J Higgins; Richard A LeCouteur; Nikhil Joshi; Danika Bannasch
Journal:  J Neuropathol Exp Neurol       Date:  2016-05-31       Impact factor: 3.685

7.  Non-thermal irreversible electroporation (N-TIRE) and adjuvant fractionated radiotherapeutic multimodal therapy for intracranial malignant glioma in a canine patient.

Authors:  P A Garcia; T Pancotto; J H Rossmeisl; N Henao-Guerrero; N R Gustafson; G B Daniel; J L Robertson; T L Ellis; R V Davalos
Journal:  Technol Cancer Res Treat       Date:  2011-02

8.  Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.

Authors:  Marion Adelfinger; Simon Bessler; Alexa Frentzen; Alexander Cecil; Johanna Langbein-Laugwitz; Ivaylo Gentschev; Aladar A Szalay
Journal:  Viruses       Date:  2015-07-20       Impact factor: 5.048

Review 9.  Advances in diagnostic and treatment modalities for intracranial tumors.

Authors:  P J Dickinson
Journal:  J Vet Intern Med       Date:  2014-05-09       Impact factor: 3.333

Review 10.  Oncolytic Viruses for Canine Cancer Treatment.

Authors:  Diana Sánchez; Gabriela Cesarman-Maus; Alfredo Amador-Molina; Marcela Lizano
Journal:  Cancers (Basel)       Date:  2018-10-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.